Efavirenz

Overview

Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K i of 2.93 nM and exhibits an IC 95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Parasitic Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reverse Transcriptase | Products > Signaling Pathways > HIV | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Endogenous Metabolite | Products > Signaling Pathways > Parasite

Product Information

• Catalog No.: HY-10572
• CAS No.: 154598-52-4
• Molecular Formula: C14H9ClF3NO2
• Molecular Weight: 315.68
• Purity: 99.93%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (6.59 mM); Clear solution
• Availability: In-stock

Source

Original product source